JP2023002670A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023002670A5 JP2023002670A5 JP2022166859A JP2022166859A JP2023002670A5 JP 2023002670 A5 JP2023002670 A5 JP 2023002670A5 JP 2022166859 A JP2022166859 A JP 2022166859A JP 2022166859 A JP2022166859 A JP 2022166859A JP 2023002670 A5 JP2023002670 A5 JP 2023002670A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- vlcdr2
- vlcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 108
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 16
- 208000034799 Tauopathies Diseases 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 13
- 102000036639 antigens Human genes 0.000 claims 13
- 108091007433 antigens Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 102000013498 tau Proteins Human genes 0.000 claims 12
- 108010026424 tau Proteins Proteins 0.000 claims 12
- 208000024827 Alzheimer disease Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 208000002109 Argyria Diseases 0.000 claims 4
- 241001554566 Argyria Species 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 4
- 206010052369 Encephalitis lethargica Diseases 0.000 claims 4
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 4
- 206010036631 Presenile dementia Diseases 0.000 claims 4
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims 4
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims 4
- 230000002308 calcification Effects 0.000 claims 4
- 210000000349 chromosome Anatomy 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- 210000000609 ganglia Anatomy 0.000 claims 4
- 230000002518 glial effect Effects 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 4
- 210000004885 white matter Anatomy 0.000 claims 4
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024146101A JP2024170459A (ja) | 2017-02-27 | 2024-08-28 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017035594 | 2017-02-27 | ||
| JP2017035594A JP2018139530A (ja) | 2017-02-27 | 2017-02-27 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| PCT/IB2018/000249 WO2018154390A1 (en) | 2017-02-27 | 2018-02-27 | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same |
| JP2019545918A JP7165996B2 (ja) | 2017-02-27 | 2018-02-27 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019545918A Division JP7165996B2 (ja) | 2017-02-27 | 2018-02-27 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146101A Division JP2024170459A (ja) | 2017-02-27 | 2024-08-28 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023002670A JP2023002670A (ja) | 2023-01-10 |
| JP2023002670A5 true JP2023002670A5 (https=) | 2023-04-26 |
Family
ID=62025891
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017035594A Pending JP2018139530A (ja) | 2017-02-27 | 2017-02-27 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| JP2019545918A Active JP7165996B2 (ja) | 2017-02-27 | 2018-02-27 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
| JP2022166859A Pending JP2023002670A (ja) | 2017-02-27 | 2022-10-18 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
| JP2024146101A Pending JP2024170459A (ja) | 2017-02-27 | 2024-08-28 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017035594A Pending JP2018139530A (ja) | 2017-02-27 | 2017-02-27 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| JP2019545918A Active JP7165996B2 (ja) | 2017-02-27 | 2018-02-27 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146101A Pending JP2024170459A (ja) | 2017-02-27 | 2024-08-28 | 認知障害を治療または予防するためのヒト化抗体、その製造プロセス、及びそれを用いた認知障害を治療または予防するための薬剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10556950B2 (https=) |
| EP (1) | EP3585810B1 (https=) |
| JP (4) | JP2018139530A (https=) |
| KR (1) | KR102701634B1 (https=) |
| CN (2) | CN111320695B (https=) |
| AR (2) | AR110875A1 (https=) |
| AU (1) | AU2018224390C1 (https=) |
| BR (1) | BR112019016490A2 (https=) |
| CA (1) | CA3052538A1 (https=) |
| CL (3) | CL2019002296A1 (https=) |
| CO (1) | CO2019008786A2 (https=) |
| CR (1) | CR20190363A (https=) |
| DO (1) | DOP2019000215A (https=) |
| EA (1) | EA201991726A1 (https=) |
| ES (1) | ES3063126T3 (https=) |
| GE (2) | GEP20227392B (https=) |
| IL (1) | IL267945B2 (https=) |
| JO (1) | JOP20180014A1 (https=) |
| MA (1) | MA47608A (https=) |
| MX (2) | MX2019009945A (https=) |
| MY (1) | MY193821A (https=) |
| NI (1) | NI201900086A (https=) |
| PE (2) | PE20191614A1 (https=) |
| PH (1) | PH12019501929A1 (https=) |
| SG (2) | SG10201913419TA (https=) |
| TW (2) | TWI848904B (https=) |
| WO (2) | WO2018154392A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2857039T3 (pl) * | 2012-05-31 | 2020-05-18 | Osaka City University | Środek terapeutyczny lub środek profilaktyczny na otępienie |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| US20210355199A1 (en) | 2018-06-28 | 2021-11-18 | University Of Virginia Patent Foundation | Compositions and methods for detecting and regulating fibronectin-integrin interaction and signaling |
| US12365724B2 (en) * | 2018-12-10 | 2025-07-22 | New York University | Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof |
| US20220381790A1 (en) | 2019-02-11 | 2022-12-01 | University Of Virginia Patent Foundation | Selection and blockade of fertilization competent male and female gametes |
| EP3934677A4 (en) | 2019-03-13 | 2022-11-16 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS TO PROMOTE ISLAND VIABILITY AND INCREASE INSULINE SECRETION |
| JP7181438B2 (ja) * | 2019-08-06 | 2022-11-30 | アプリノイア セラピューティクス リミテッド | 病理学的タウ種に結合する抗体及びその使用 |
| CN115605594A (zh) * | 2020-06-02 | 2023-01-13 | 帝人制药株式会社（Jp） | 抗igf-1受体人源化抗体 |
| CA3183835A1 (en) * | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN115322255B (zh) * | 2022-04-25 | 2025-03-07 | 上海药明生物医药有限公司 | 一种优化的Fc变体及其应用 |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025207501A1 (en) * | 2024-03-26 | 2025-10-02 | Merck Sharp & Dohme Llc | Crystals of anti-human tau monoclonal antibody |
| CN119080924B (zh) * | 2024-07-04 | 2025-02-25 | 上海交通大学医学院附属第九人民医院 | 一种单克隆免疫球蛋白及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| JP4754352B2 (ja) | 2003-08-29 | 2011-08-24 | 株式会社リバース・プロテオミクス研究所 | タンパク質の固定化方法 |
| AU2004297616B2 (en) | 2003-12-04 | 2008-12-18 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| CA2813493C (en) | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| MX350311B (es) | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| PL2857039T3 (pl) * | 2012-05-31 | 2020-05-18 | Osaka City University | Środek terapeutyczny lub środek profilaktyczny na otępienie |
| NZ630542A (en) * | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| CA2896066C (en) | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| BR112015030356A2 (pt) | 2013-06-10 | 2017-12-05 | Ipierian Inc | métodos de tratamento de uma taupatia |
| AU2014368696A1 (en) | 2013-12-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Humanized anti-Tau(pS422) antibodies and methods of use |
| AR100978A1 (es) * | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| CA2961439A1 (en) | 2014-11-05 | 2016-05-12 | Genentech, Inc. | Anti-fgfr2/3 antibodies and methods using same |
| WO2016112078A2 (en) | 2015-01-08 | 2016-07-14 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
-
2017
- 2017-02-27 JP JP2017035594A patent/JP2018139530A/ja active Pending
-
2018
- 2018-02-25 WO PCT/IB2018/000267 patent/WO2018154392A1/en not_active Ceased
- 2018-02-26 TW TW107106444A patent/TWI848904B/zh active
- 2018-02-26 TW TW113125487A patent/TW202506718A/zh unknown
- 2018-02-27 KR KR1020197024146A patent/KR102701634B1/ko active Active
- 2018-02-27 MY MYPI2019004787A patent/MY193821A/en unknown
- 2018-02-27 AR ARP180100454A patent/AR110875A1/es unknown
- 2018-02-27 MA MA047608A patent/MA47608A/fr unknown
- 2018-02-27 CR CR20190363A patent/CR20190363A/es unknown
- 2018-02-27 PE PE2019001541A patent/PE20191614A1/es unknown
- 2018-02-27 US US15/906,773 patent/US10556950B2/en active Active
- 2018-02-27 JO JOP/2018/0014A patent/JOP20180014A1/ar unknown
- 2018-02-27 BR BR112019016490A patent/BR112019016490A2/pt unknown
- 2018-02-27 IL IL267945A patent/IL267945B2/en unknown
- 2018-02-27 SG SG10201913419TA patent/SG10201913419TA/en unknown
- 2018-02-27 WO PCT/IB2018/000249 patent/WO2018154390A1/en not_active Ceased
- 2018-02-27 JP JP2019545918A patent/JP7165996B2/ja active Active
- 2018-02-27 AU AU2018224390A patent/AU2018224390C1/en active Active
- 2018-02-27 PE PE2024001024A patent/PE20241514A1/es unknown
- 2018-02-27 ES ES18718907T patent/ES3063126T3/es active Active
- 2018-02-27 GE GEAP201815170A patent/GEP20227392B/en unknown
- 2018-02-27 CN CN202010117151.0A patent/CN111320695B/zh active Active
- 2018-02-27 SG SG11201907548PA patent/SG11201907548PA/en unknown
- 2018-02-27 CN CN201880008302.XA patent/CN110382528A/zh active Pending
- 2018-02-27 EP EP18718907.1A patent/EP3585810B1/en active Active
- 2018-02-27 MX MX2019009945A patent/MX2019009945A/es unknown
- 2018-02-27 EA EA201991726A patent/EA201991726A1/ru unknown
- 2018-02-27 CA CA3052538A patent/CA3052538A1/en active Pending
- 2018-02-27 GE GEAP202215170A patent/GEAP202215170A/en unknown
-
2019
- 2019-08-09 NI NI201900086A patent/NI201900086A/es unknown
- 2019-08-13 CO CONC2019/0008786A patent/CO2019008786A2/es unknown
- 2019-08-13 CL CL2019002296A patent/CL2019002296A1/es unknown
- 2019-08-15 DO DO2019000215A patent/DOP2019000215A/es unknown
- 2019-08-20 MX MX2023013246A patent/MX2023013246A/es unknown
- 2019-08-20 PH PH12019501929A patent/PH12019501929A1/en unknown
- 2019-08-22 AR ARP190102386A patent/AR117952A2/es unknown
-
2020
- 2020-01-17 US US16/746,725 patent/US10894829B2/en active Active
- 2020-12-15 US US17/122,325 patent/US11739143B2/en active Active
-
2021
- 2021-09-13 CL CL2021002389A patent/CL2021002389A1/es unknown
-
2022
- 2022-10-18 JP JP2022166859A patent/JP2023002670A/ja active Pending
-
2024
- 2024-02-02 CL CL2024000339A patent/CL2024000339A1/es unknown
- 2024-08-28 JP JP2024146101A patent/JP2024170459A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002670A5 (https=) | ||
| JP7337204B2 (ja) | 単鎖可変フラグメントｃｄ３結合タンパク質 | |
| JP7001474B2 (ja) | 非免疫原性単一ドメイン抗体 | |
| HRP20192267T1 (hr) | Terapeutski agens ili profilaktički agens za demenciju | |
| JP2020506898A5 (https=) | ||
| JP2022521750A5 (https=) | ||
| JP2019503990A (ja) | 改良された血清アルブミン結合剤 | |
| RU2012101485A (ru) | Биспецифические четырехвалентные антигенсвязывающие белки | |
| JP2014502141A5 (https=) | ||
| JP2020508666A5 (https=) | ||
| JP7109467B2 (ja) | タウに特異的に結合する結合分子 | |
| JP6943764B2 (ja) | Ｉｌ−１７ａ結合ポリペプチド | |
| RU2013120544A (ru) | Фармацевтическая композиция | |
| JP2020530285A5 (https=) | ||
| JP2017534296A5 (https=) | ||
| CN111447951A (zh) | 与tau特异性结合的结合分子 | |
| JP2025032102A5 (https=) | ||
| JP2020516603A5 (https=) | ||
| JP2021520210A5 (https=) | ||
| JP2018505651A5 (https=) | ||
| JP2020532572A5 (https=) | ||
| JP2024544936A5 (https=) | ||
| JP6678661B2 (ja) | 新規ポリペプチド | |
| JP2018515453A5 (https=) | ||
| JP2022518282A5 (https=) |